A similar "broad activation" principle serves as a rationale for systemic interleukin-2 (IL-2) administration, which is currently used as anti-cancer immunotherapy in renal cell cancer and metastatic melanoma [25]. The gene discussed is IL2; the disease is metastatic melanoma.